Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model-Reference-Cited by-同舟云学术

Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model

Published:2023-09-13 Issue:1 Volume:30 Page:
ISSN:1071-7544
Container-title:Drug Delivery
language:en
Short-container-title:Drug Delivery

Author:

Connor Robert J.¹,Clift Renee²,Kang David W.¹

Affiliation:

1. Drug Delivery, Halozyme Therapeutics, Inc., San Diego, CA, USA

2. Formerly of Halozyme Therapeutics, Inc., San Diego, CA, USA

Funder

Halozyme Therapeutics, Inc.

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/10717544.2023.2252999

Reference39 articles.

1. Amgen Inc. (2021). Highlights of Prescribing Information. REPATHA (evolcumab) injection for subcutaneous use. https://www.pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/repatha/repatha_pi_hcp_english.pdf [last accessed 23 March 2022].

2. Bittner B, Locke KW, Maneval DC, et al. (2022). ENHANZE® drug delivery technology. Oxford (UK): S. Karger Publishers Ltd.

3. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities

4. A recombinant human enzyme for enhanced interstitial transport of therapeutics

5. Hyaluronidase: from clinical applications to molecular and cellular mechanisms

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies;Journal of Controlled Release;2024-10

2. Towards more tolerable subcutaneous administration: Review of contributing factors for improving combination product design;Advanced Drug Delivery Reviews;2024-06